Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree

  • Gary R. Cutter1Email author,
  • Volker Knappertz2, 3,
  • Nissim Sasson4 and
  • David Ladkani5
BMC NeurologyBMC series – open, inclusive and trusted201616:176

https://doi.org/10.1186/s12883-016-0702-4

Received: 26 January 2016

Accepted: 12 September 2016

Published: 17 September 2016

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
26 Jan 2016 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
12 Sep 2016 Editorially accepted
17 Sep 2016 Article published 10.1186/s12883-016-0702-4

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, USA
(2)
Department of Neurology and Psychiatry, Heinrich-Heine University, Düsseldorf, Germany
(3)
Teva Pharmaceutical Industries, Frazer, USA
(4)
Teva Pharmaceutical Industries Abic, Ltd, Netanya, Israel
(5)
Teva Pharmaceutical Industries, Petach Tikva, Israel

Advertisement